GlassScriptPhysician profile
Gina Bevando
NPI 1245896257
$6,977.04
in general payments reported to CMS, 2019-2025
31 companies · $699 in 2025
The $699 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,822 · 2022: $1,233 · 2023: $1,398 · 2024: $1,826 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.51 |
| Education | $142.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,428.11 | 2021-2025 | Relistor, Xifaxan, Plenvu |
| Abbvie INC. | $1,083.39 | 2021-2025 | |
| Gilead Sciences, INC. | $955.64 | 2021-2025 | |
| Qol Medical, LLC | $647.02 | 2022-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $463.72 | 2021-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $362.90 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $298.78 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $270.71 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $269.11 | 2021-2024 | Entyvio |
| Celgene Corporation | $174.89 | 2021-2024 | Zeposia |
| Genzyme Corporation | $121.46 | 2022-2024 | |
| Vivus LLC | $106.72 | 2024-2025 | Pancreaze |
| Ferring Pharmaceuticals INC. | $104.26 | 2024 | Clenpiq, Rebyota |
| Evoke Pharma, INC. | $79.21 | 2022-2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $72.53 | 2021-2024 | Ocaliva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $68.93 | 2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $58.84 | 2021-2024 | Dificid |
| Lucid Diagnostics INC. | $55.49 | 2022-2023 | |
| Endogastric Solutions, INC | $54.06 | 2022 | |
| Pfizer INC. | $44.07 | 2023-2024 | |
| Daiichi Sankyo INC. | $38.23 | 2021 | |
| Ironwood Pharmaceuticals, INC | $34.61 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $27.19 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $27.09 | 2024 | Resmetirom |
| Echosens North America, INC. | $25.03 | 2024 | Fibroscan |
| Exact Sciences Corporation | $22.76 | 2023 | Cologuard Collection Kit |
| Celltrion USA INC. | $22.11 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $18.38 | 2023 | Onpattro |
| Redhill Biopharma INC. | $14.45 | 2021 | |
| Braintree Laboratories, INC. | $14.07 | 2022 | |
| W. L. Gore & Associates, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Bevando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.